Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

  1. Moore, K.N.
  2. O'Malley, D.M.
  3. Vergote, I.
  4. Martin, L.P.
  5. Gonzalez-Martin, A.
  6. Malek, K.
  7. Birrer, M.J.
Aldizkaria:
Gynecologic Oncology

ISSN: 1095-6859,  0090-8258

Argitalpen urtea: 2018

Alea: 151

Zenbakia: 1

Orrialdeak: 46-52

Mota: Artikulua

DOI: 10.1016/J.YGYNO.2018.07.017 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus